Galmed Pharmaceuticals Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $4.0M
- Price
- $0.5231
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.49%
- Volume
- 45.5K
About
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Quick stats
Shares outstanding7.7M
Computed float6.3M
Float / shares82.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001595353
Websitehttps://www.galmedpharma.com
AI Summary
AI-generated1/13
standardbullishoperations update
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
Galmed Pharmaceuticals announced the development of a new orally dispersible film (ODF) formulation of its SCD1 inhibitor Aramchol for Parkinson's disease, targeting a $6 billion market.
The ODF formulation demonstrated 150% higher systemic bioavailability and a 300% increase in CNS exposure compared to conventional oral administration, while also addressing dysphagia affecting up to 80% of patients.
Management views Aramchol's PD program as an ideal out-licensing candidate due to its novel mechanism, established safety profile, and enhanced delivery technology.